BIOMAT Database Logo BIOMAT Database Logo

Treatment of Langerhans cell histiocytosis in children with etoposide. 1992

E Ishii, and A Matsuzaki, and J Okamura, and T Inoue, and M Kajiwara, and T Uozumi, and N Yoshida, and S Miyazaki, and K Miyake, and T Matsumoto
Department of Pediatrics, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

Ten children with Langerhans cell histiocytosis (LCH) were treated with etoposide. For five patients, this was the initial diagnosis. The other five had failed to respond to previous therapies. Etoposide (100 mg/m2) was given intravenously twice a week for 4 weeks, followed by maintenance therapy every 2 to 4 weeks for 2 years. All 10 patients responded to etoposide, and 6 of them (60%) have been in complete remission for 3 to 36 months without any side effects. One patient relapsed with diabetes insipidus, one with a soft tissue mass, and two others developed multiple bone lesions. Chemotherapy with etoposide appears to be effective and safe for the treatment of children with systemic LCH.

UI MeSH Term Description Entries
D008297 Male Males
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006646 Histiocytosis, Langerhans-Cell A group of disorders resulting from the abnormal proliferation of and tissue infiltration by LANGERHANS CELLS which can be detected by their characteristic Birbeck granules (X bodies), or by monoclonal antibody staining for their surface CD1 ANTIGENS. Langerhans-cell granulomatosis can involve a single organ, or can be a systemic disorder. Histiocytosis X,Langerhans-Cell Granulomatosis,Langerhans-Cell Histiocytosis,Hand-Schueller-Christian Disease,Hand-Schueller-Christian Syndrome,Hand-Schüller-Christian Disease,Hand-Schüller-Christian Syndrome,Hashimoto-Pritzger Disease,Histiocytosis, Generalized,Histiocytosis-X,Langerhans Cell Granulomatosis,Langerhans Cell Granulomatosis, Pulmonary,Langerhans Cell Histiocytosis,Letterer-Siwe Disease,Non-Lipid Reticuloendotheliosis,Pulmonary Histiocytosis X,Pulmonary Langerhans Cell Granulomatosis,Schueller-Christian Disease,Systemic Aleukemic Reticuloendotheliosis,Type 2 Histiocytosis,Aleukemic Reticuloendothelioses, Systemic,Aleukemic Reticuloendotheliosis, Systemic,Cell Granulomatoses, Langerhans,Cell Granulomatosis, Langerhans,Cell Histiocytoses, Langerhans,Cell Histiocytosis, Langerhans,Disease, Hand-Schueller-Christian,Disease, Hand-Schüller-Christian,Disease, Hashimoto-Pritzger,Disease, Letterer-Siwe,Disease, Schueller-Christian,Diseases, Hashimoto-Pritzger,Generalized Histiocytoses,Generalized Histiocytosis,Granulomatoses, Langerhans Cell,Granulomatosis, Langerhans Cell,Granulomatosis, Langerhans-Cell,Hand Schueller Christian Disease,Hand Schueller Christian Syndrome,Hand Schüller Christian Disease,Hand Schüller Christian Syndrome,Hashimoto Pritzger Disease,Hashimoto-Pritzger Diseases,Histiocytoses, Generalized,Histiocytoses, Langerhans Cell,Histiocytoses, Type 2,Histiocytosis X, Pulmonary,Histiocytosis, Langerhans Cell,Histiocytosis, Type 2,Langerhans Cell Granulomatoses,Langerhans Cell Histiocytoses,Letterer Siwe Disease,Non Lipid Reticuloendotheliosis,Non-Lipid Reticuloendothelioses,Reticuloendothelioses, Non-Lipid,Reticuloendothelioses, Systemic Aleukemic,Reticuloendotheliosis, Non-Lipid,Reticuloendotheliosis, Systemic Aleukemic,Schueller Christian Disease,Syndrome, Hand-Schueller-Christian,Syndrome, Hand-Schüller-Christian,Systemic Aleukemic Reticuloendothelioses,Type 2 Histiocytoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

E Ishii, and A Matsuzaki, and J Okamura, and T Inoue, and M Kajiwara, and T Uozumi, and N Yoshida, and S Miyazaki, and K Miyake, and T Matsumoto
Etoposide in the treatment of six children with Langerhans cell histiocytosis (histiocytosis X)
January 1991, Medical and pediatric oncology,
E Ishii, and A Matsuzaki, and J Okamura, and T Inoue, and M Kajiwara, and T Uozumi, and N Yoshida, and S Miyazaki, and K Miyake, and T Matsumoto
Treatment of adult Langerhans cell histiocytosis with etoposide.
July 1992, Journal of the American Academy of Dermatology,
E Ishii, and A Matsuzaki, and J Okamura, and T Inoue, and M Kajiwara, and T Uozumi, and N Yoshida, and S Miyazaki, and K Miyake, and T Matsumoto
[Etoposide (VP16) treatment of Langerhans-cell histiocytosis].
April 1991, Revista clinica espanola,
E Ishii, and A Matsuzaki, and J Okamura, and T Inoue, and M Kajiwara, and T Uozumi, and N Yoshida, and S Miyazaki, and K Miyake, and T Matsumoto
Successful treatment of multisystem Langerhans cell histiocytosis (histiocytosis X) with etoposide.
August 1994, The American journal of pediatric hematology/oncology,
E Ishii, and A Matsuzaki, and J Okamura, and T Inoue, and M Kajiwara, and T Uozumi, and N Yoshida, and S Miyazaki, and K Miyake, and T Matsumoto
Etoposide in Langerhans cell histiocytosis.
January 1996, Pediatric hematology and oncology,
E Ishii, and A Matsuzaki, and J Okamura, and T Inoue, and M Kajiwara, and T Uozumi, and N Yoshida, and S Miyazaki, and K Miyake, and T Matsumoto
Etoposide (VP16) in the treatment of multisystem Langerhans cell histiocytosis (histiocytosis X).
January 1989, Medical and pediatric oncology,
E Ishii, and A Matsuzaki, and J Okamura, and T Inoue, and M Kajiwara, and T Uozumi, and N Yoshida, and S Miyazaki, and K Miyake, and T Matsumoto
Etoposide in Langerhans cell histiocytosis in children: a preliminary experience.
January 1996, Pediatric hematology and oncology,
E Ishii, and A Matsuzaki, and J Okamura, and T Inoue, and M Kajiwara, and T Uozumi, and N Yoshida, and S Miyazaki, and K Miyake, and T Matsumoto
Re: "Etoposide in the treatment of six children with Langerhans cell histiocytosis (histiocytosis X)" by Viana et al.
January 1993, Medical and pediatric oncology,
E Ishii, and A Matsuzaki, and J Okamura, and T Inoue, and M Kajiwara, and T Uozumi, and N Yoshida, and S Miyazaki, and K Miyake, and T Matsumoto
[Treatment of langerhans cell histiocytosis in children].
January 2011, Lijecnicki vjesnik,
E Ishii, and A Matsuzaki, and J Okamura, and T Inoue, and M Kajiwara, and T Uozumi, and N Yoshida, and S Miyazaki, and K Miyake, and T Matsumoto
Langerhans-cell histiocytosis--excellent response to etoposide.
July 1991, Clinical and experimental dermatology,
Copied contents to your clipboard!